HUP0302643A2 - Vakcina - Google Patents

Vakcina

Info

Publication number
HUP0302643A2
HUP0302643A2 HU0302643A HUP0302643A HUP0302643A2 HU P0302643 A2 HUP0302643 A2 HU P0302643A2 HU 0302643 A HU0302643 A HU 0302643A HU P0302643 A HUP0302643 A HU P0302643A HU P0302643 A2 HUP0302643 A2 HU P0302643A2
Authority
HU
Hungary
Prior art keywords
vaccine
virus preparations
cleaved
packages
vaccines
Prior art date
Application number
HU0302643A
Other languages
English (en)
Inventor
Brigitte Desiree Alberte Colau
Marguerite Deschamps
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HUP0302643A2 publication Critical patent/HUP0302643A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány tárgyát hasított burkolt víruskészítményeket - de nemhasított influenza víruskészítményeket - tartalmazóvakcinakiszerelések alkalmazása képezi intranazális bejuttatásraalkalmas vakcinakiszerelés gyártására. A találmány tárgyát képeziktovábbá eljárások ilyen kiszerelések gyártására, és ilyen vakcinákalkalmazása betegség megelőzésére vagy kezelésére. Ó
HU0302643A 2000-10-02 2001-10-01 Vakcina HUP0302643A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024089.5A GB0024089D0 (en) 2000-10-02 2000-10-02 Novel compounds
PCT/EP2001/011326 WO2002028422A2 (en) 2000-10-02 2001-10-01 Split enveloped virus preparation for intranasal delivery

Publications (1)

Publication Number Publication Date
HUP0302643A2 true HUP0302643A2 (hu) 2003-11-28

Family

ID=9900509

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302643A HUP0302643A2 (hu) 2000-10-02 2001-10-01 Vakcina

Country Status (16)

Country Link
US (1) US20040022808A1 (hu)
EP (1) EP1324769A2 (hu)
JP (1) JP2004510744A (hu)
KR (1) KR20030031200A (hu)
CN (1) CN1477971A (hu)
AU (1) AU2002213984A1 (hu)
BR (1) BR0114393A (hu)
CA (1) CA2427842A1 (hu)
CZ (1) CZ2003931A3 (hu)
GB (1) GB0024089D0 (hu)
HU (1) HUP0302643A2 (hu)
IL (1) IL155072A0 (hu)
NO (1) NO20031483L (hu)
PL (1) PL362705A1 (hu)
WO (1) WO2002028422A2 (hu)
ZA (1) ZA200302522B (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2503774C (en) 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
AU2004299057B2 (en) * 2003-12-17 2010-06-24 Wyeth Llc Methods for porducing storage stable viruses and immunogenic compositions thereof
CN1305526C (zh) * 2003-12-29 2007-03-21 薛平 乙型脑炎病毒裂解疫苗及其制备方法
EP1722815A1 (en) 2004-03-09 2006-11-22 Chiron Corporation Influenza virus vaccines
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
KR20080069232A (ko) 2005-11-04 2008-07-25 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2377552A3 (en) 2005-11-04 2013-05-15 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
BRPI0707300B8 (pt) 2006-01-27 2021-05-25 Novartis Ag vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
EP2004226A1 (en) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Storage of influenza vaccines without refrigeration
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
BRPI0716536A2 (pt) 2006-09-11 2013-09-24 Novartis Ag produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
CA2696090C (en) * 2007-08-28 2017-06-13 Baxter International Inc. Method for producing viral vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8685654B2 (en) 2007-12-24 2014-04-01 Novartis Ag Assays for adsorbed influenza vaccines
US20110014230A1 (en) 2008-03-18 2011-01-20 Novartis Ag preparation of influenza virus vaccine antigens
WO2010052214A2 (en) 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
JP5642712B2 (ja) 2009-02-10 2014-12-17 ノバルティス アーゲー 少ない量のスクアレンを含むインフルエンザワクチン
US20120093859A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
ES2394797T3 (es) 2009-05-21 2013-02-05 Novartis Ag Genética inversa usando promotores no endógenos de pol l
JP5716297B2 (ja) 2009-06-25 2015-05-13 Jnc株式会社 クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
AU2010293902A1 (en) 2009-09-10 2012-03-22 Novartis Ag Combination vaccines against respiratory tract diseases
EP2480889B1 (en) 2009-09-25 2015-03-25 GlaxoSmithKline Biologicals S.A. Immunodiffusion assay for influenza virus
CN102741399A (zh) 2009-10-20 2012-10-17 诺华有限公司 用于病毒拯救的改良反向遗传方法
CA2797059A1 (en) 2010-05-03 2011-11-10 Glaxosmithkline Biologicals S.A. Novel method
KR20130079398A (ko) 2010-05-06 2013-07-10 노파르티스 아게 미생물 불활성화를 위한 유기 과산화 화합물
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
EP3827843A1 (en) 2010-06-01 2021-06-02 Seqirus UK Limited Concentration of influenza vaccine antigens without lyophilization
WO2011151726A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
NZ704005A (en) * 2012-08-01 2016-07-29 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
CN105828835A (zh) 2013-05-10 2016-08-03 诺华股份有限公司 避免流感疫苗中的发作性嗜睡病风险
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
CN105473712B (zh) * 2013-08-30 2022-05-27 葛兰素史密丝克莱恩生物有限公司 在细胞培养物中大规模生产病毒
KR20160068972A (ko) 2013-11-15 2016-06-15 노파르티스 아게 잔여 세포 배양 불순물의 제거
CA2897038C (en) 2014-07-14 2016-10-04 Novicol International Holding Inc. Microbicidal composition comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
WO2016096688A1 (en) 2014-12-16 2016-06-23 Glaxosmithkline Biologicals S.A. A method for a large scale virus purification
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
KR102576962B1 (ko) 2015-07-07 2023-09-11 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
MX2021010194A (es) 2019-02-25 2022-01-24 Seqirus Uk Ltd Vacunas contra la influenza multivalentes adyuvantadas.
MX2022005513A (es) 2019-11-07 2022-06-08 Seqirus Uk Ltd Composiciones y metodos para producir una vacuna viral con tama?o de particula reducido.
AU2020389047A1 (en) 2019-11-18 2022-06-02 Seqirus Pty Ltd. Method for producing reassortant influenza viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4005528C2 (de) * 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
PL355287A1 (en) * 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine

Also Published As

Publication number Publication date
GB0024089D0 (en) 2000-11-15
US20040022808A1 (en) 2004-02-05
ZA200302522B (en) 2004-06-30
IL155072A0 (en) 2003-10-31
NO20031483D0 (no) 2003-04-01
BR0114393A (pt) 2003-08-26
PL362705A1 (en) 2004-11-02
NO20031483L (no) 2003-05-28
WO2002028422A3 (en) 2002-08-29
CZ2003931A3 (cs) 2003-10-15
CN1477971A (zh) 2004-02-25
EP1324769A2 (en) 2003-07-09
AU2002213984A1 (en) 2002-04-15
JP2004510744A (ja) 2004-04-08
KR20030031200A (ko) 2003-04-18
WO2002028422A2 (en) 2002-04-11
CA2427842A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
HUP0302643A2 (hu) Vakcina
HUP0202846A2 (hu) Intranazális influenzavírus-oltóanyag
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
HUP0203056A1 (hu) Vakcinakészítmény
HUP0400445A2 (hu) Új vakcinakészítmények
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
CY1107550T1 (el) Συνδυαστικα εμβολια μηνιγγιτιδας b/c
DE122011100037I1 (de) Rekombinante influenzaviren zur vakzinherstellung und gentherapie.
HUP0202885A2 (hu) Oltóanyagok
HUP0303996A2 (hu) Vakcinakészítmények
RS51699B (sr) Beta-amiloid-analog-t-ćelijski-epitop vakcina
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
HUP0402067A2 (hu) Oltóanyagok
NO20015073L (no) Vaksiner
HUP0203335A1 (hu) Vakcina
GB2386072A (en) Novel vaccine
HUP0301349A2 (hu) IL-11-tartalmú készítmények
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
HUP0302874A2 (hu) Eljárás risperidon előállítására
HUP0401605A2 (hu) Szembetegségek kezelésére szolgáló integrin gátlók
HUP0300559A2 (hu) A trombopoietin receptort moduláló peptidek
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2006071896A3 (en) Epitope-based sars vaccine